Helen Zukin1, Brenda Eskenazi1, Nina Holland1, Kim G Harley2. 1. Center for Environmental Research and Children's Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA. 2. Center for Environmental Research and Children's Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA. Electronic address: kharley@berkeley.edu.
Abstract
BACKGROUND: Phthalates are a group of endocrine disrupting chemicals that are heavily used throughout industry in flexible plastic and personal-care products. As a result, detectable levels of their metabolites are readily found in humans. Some studies have shown associations of phthalates with diabetes, but associations with gestational diabetes mellitus (GDM) are less clear. OBJECTIVE: To investigate the association of 11 prenatal urinary phthalate metabolites and development of GDM, impaired glucose tolerance (IGT), continuous plasma glucose level, and excessive gestational weight gain (GWG) in a population of pregnant Latina women (N = 415) enrolled in the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) cohort study. METHODS: Phthalate metabolite levels were measured via mass spectrometry from two urine samples collected in the end of the first and second trimester. Maternal plasma glucose levels, prior diabetes diagnosis, GDM diagnosis, and weight gain were abstracted from medical records. Multiple regression was used to evaluate the association between the average of the two urinary phthalate metabolites levels and maternal metabolic outcomes. In our sensitivity analysis, phthalate levels were categorized by level (as quartiles of exposure) and by timing of urine sample collection (as taken in first and second half of pregnancy). RESULTS: Consistent with findings from a nationally representative sample, all of the individual phthalate metabolites were detected in majority of mothers. Thirty-one mothers (7.5%) were diagnosed with GDM, 49 mothers (14.7%) displayed IGT, and 223 mothers (55.1%) gained an excessive amount of weight during their pregnancy. MEP concentrations were associated with an increased odds of excessive GWG (OR: 1.1, 95% CI: 1.0 to 1.3). We did not find an association between any phthalate metabolite and any maternal glucose outcome. CONCLUSION: Contrary to previous studies, our findings do not support an association of prenatal phthalate levels and increased odds for hyperglycemia, IGT, or GDM. But, we did find an increased odds of excessive GWG, a well-known risk factor for GDM.
BACKGROUND: Phthalates are a group of endocrine disrupting chemicals that are heavily used throughout industry in flexible plastic and personal-care products. As a result, detectable levels of their metabolites are readily found in humans. Some studies have shown associations of phthalates with diabetes, but associations with gestational diabetes mellitus (GDM) are less clear. OBJECTIVE: To investigate the association of 11 prenatal urinary phthalate metabolites and development of GDM, impaired glucose tolerance (IGT), continuous plasma glucose level, and excessive gestational weight gain (GWG) in a population of pregnant Latina women (N = 415) enrolled in the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) cohort study. METHODS: Phthalate metabolite levels were measured via mass spectrometry from two urine samples collected in the end of the first and second trimester. Maternal plasma glucose levels, prior diabetes diagnosis, GDM diagnosis, and weight gain were abstracted from medical records. Multiple regression was used to evaluate the association between the average of the two urinary phthalate metabolites levels and maternal metabolic outcomes. In our sensitivity analysis, phthalate levels were categorized by level (as quartiles of exposure) and by timing of urine sample collection (as taken in first and second half of pregnancy). RESULTS: Consistent with findings from a nationally representative sample, all of the individual phthalate metabolites were detected in majority of mothers. Thirty-one mothers (7.5%) were diagnosed with GDM, 49 mothers (14.7%) displayed IGT, and 223 mothers (55.1%) gained an excessive amount of weight during their pregnancy. MEP concentrations were associated with an increased odds of excessive GWG (OR: 1.1, 95% CI: 1.0 to 1.3). We did not find an association between any phthalate metabolite and any maternal glucose outcome. CONCLUSION: Contrary to previous studies, our findings do not support an association of prenatal phthalate levels and increased odds for hyperglycemia, IGT, or GDM. But, we did find an increased odds of excessive GWG, a well-known risk factor for GDM.
Authors: Tamarra M James-Todd; John D Meeker; Tianyi Huang; Russ Hauser; Kelly K Ferguson; Janet W Rich-Edwards; Thomas F McElrath; Ellen W Seely Journal: Environ Int Date: 2016-09-17 Impact factor: 9.621
Authors: Denise M Scholtens; Alan Kuang; Lynn P Lowe; Jill Hamilton; Jean M Lawrence; Yael Lebenthal; Wendy J Brickman; Peter Clayton; Ronald C Ma; David McCance; Wing Hung Tam; Patrick M Catalano; Barbara Linder; Alan R Dyer; William L Lowe; Boyd E Metzger Journal: Diabetes Care Date: 2019-01-07 Impact factor: 19.112
Authors: Jay H Lubin; Joanne S Colt; David Camann; Scott Davis; James R Cerhan; Richard K Severson; Leslie Bernstein; Patricia Hartge Journal: Environ Health Perspect Date: 2004-12 Impact factor: 9.031
Authors: Shruthi Mahalingaiah; John D Meeker; Kimberly R Pearson; Antonia M Calafat; Xiaoyun Ye; John Petrozza; Russ Hauser Journal: Environ Health Perspect Date: 2008-02 Impact factor: 9.031
Authors: Emily S Barrett; Matthew Corsetti; Drew Day; Sally W Thurston; Christine T Loftus; Catherine J Karr; Kurunthachalam Kannan; Kaja Z LeWinn; Alicia K Smith; Roger Smith; Frances A Tylavsky; Nicole R Bush; Sheela Sathyanarayana Journal: Environ Int Date: 2022-01-07 Impact factor: 9.621